Coinfection
HIV/HCV Coinfected Have Stronger CD8 T-cell Response to HCV
- Details
- Category: HIV/HCV Coinfection
- Published on Friday, 06 May 2011 09:35
- Written by Liz Highleyman
HIV positive people coinfected with hepatitis C virus (HCV) demonstrated stronger CD8 T-cell responses against HCV, which may contribute to accelerated liver disease progression.
Treatment Interruption Spurs Fibrosis in HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 26 April 2011 14:28
- Written by Liz Highleyman
Stopping antiretroviral therapy led to liver fibrosis progression in HIV/HCV coinfected people, an effect that was not fully attributable to increased HIV viral load or reduced CD4 cell count.
CROI 2011: Acute Hepatitis C Treatment for HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Monday, 21 March 2011 08:29
- Written by Liz Highleyman
About 65% of coinfected patients with HCV genotypes 1 or 4, and 81% with genotypes 2 or 3, achieved sustained response to interferon-based therapy started during acute infection, researchers reported at CROI 2011.
EASL 2011: HIV/HCV Coinfection among HIV Positive Gay Men
- Details
- Category: HIV/HCV Coinfection
- Published on Saturday, 23 April 2011 14:33
- Written by Liz Highleyman
Researchers at EASL presented further data on outbreaks of sexually transmitted HCV among HIV positive men who have sex with men. Sustained response rates are high when interferon-based therapy is started during acute infection, but re-infection after treatment is common in this population. 
Tenofovir Remains Effective against Hepatitis B Virus after 5 Years in HIV/HBV Coinfected Patients
- Details
- Category: HIV/HBV Coinfection
- Published on Friday, 25 February 2011 03:53
- Written by Liz Highleyman
Tenofovir (Viread, also in the Truvada and Atripla combination pills) continues to potently suppress both hepatitis B virus (HBV) and HIV in coinfected patients for at least 5 years, according to a study published in the December 2010 issue of Gastroenterology. The findings support current guidelines recommending that HIV/HBV coinfected people should receive an antiretroviral therapy (ART) regimen that includes drugs with dual action against both viruses.
EASL 2011: Kidney Function in HIV/HBV Coinfected People on Tenofovir
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 19 April 2011 09:34
- Written by Liz Highleyman
Impaired kidney function among people with HIV, HBV, and HIV/HBV coinfection taking tenofovir mainly occurred in those with pre-existing risk factors, researchers reported at EASL 2011. 
ICAAC 2011: HCV Drug Telaprevir Shows No Problematic Interactions with Raltegravir
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 04 January 2011 00:00
- Written by Liz Highleyman
The new hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) does not appear to have clinically relevant drug-drug interactions with the HIV integrase inhibitor raltegravir (Isentress), according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
EASL 2011: Liver Disease Progression in HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 12 April 2011 14:50
- Written by Liz Highleyman
Liver stiffness measured by FibroScan is a good predictor of liver cancer, end-stage liver disease or death among people with HIV/HCV coinfection, researchers reported as EASL 2011.
Coinfected People May Control HIV but not HBV on a Tenofovir Regimen
- Details
- Category: HIV/HBV Coinfection
- Published on Friday, 10 December 2010 12:48
- Written by Liz Highleyman
More then one-third of people coinfected with HIV and hepatitis B virus (HBV) did not achieve or maintain HBV suppression after 1 year of taking tenofovir (Viread), even though they had undetectable HIV viral load indicating good adherence, according to study findings presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston.
Web Design and Development by